BioMarin Pharma (BMRN) Tops Q2 EPS by 8c, Affirms FY Revenue Guidance, Lowers R&D Expense Guidance
Tweet
Share
E-mail
Get Alerts BMRN Hot Sheet
Price: $55.90 --0%
Revenue Growth %: +13.2%
Financial Fact:
NET INCOME (LOSS): -42.8M
Today's EPS Names:
MAYS, CRMT, REPL, More
Revenue Growth %: +13.2%
Financial Fact:
NET INCOME (LOSS): -42.8M
Today's EPS Names:
MAYS, CRMT, REPL, More
Join SI Premium – FREE
BioMarin Pharma (NASDAQ: BMRN) reported Q2 EPS of ($0.09), $0.08 better than the analyst estimate of ($0.17). Revenue for the quarter came in at $372.8 billion versus the consensus estimate of $3.62 billion.
GUIDANCE:
BioMarin Pharma sees FY2018 revenue of $1.47-1.53 billion.
BioMarin Pharma sees FY2018 R&D expense of of $645-685 million, prior was for $680-710 million
For earnings history and earnings-related data on BioMarin Pharma (BMRN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Korn Ferry (KFY) Tops Q4 EPS by 2c, Beats on Revenue; Offers Q1 Guidance
- AMC Entertainment prices $200M stock offering to redeem senior notes
- Primoris cuts 2026 outlook on renewables cost overruns, COO exits
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
